Bellicum
bellicum.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review
Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today.The decision applies to phase 1/phase 2 trials designed to evaluate the safety and preliminary efficacy o
Read more
Report
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
Read more
Report
Bellicum Pharma (BLCM) Reports Positive Interim Data from Phase 1/2 GoCAR-T Studies, Announces 20.6M Share Private Placement at $1.70/sh
Read more
Report
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe Safety Switch
Read more
Report
Bellicum Reports FDA Lifted Clinical Hold on BPX-601Phase 1/2 Clinical Trial
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clini
Read more
Report
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company
Read more
Report
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
--Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 575,000 shares of its Series 1 prefer
Read more
Report
Is Bellicum Pharmaceuticals Stock Now a Strong Buy?
Bellicum Pharmaceuticals' lead product candidate is back on track. Should investors buy this news?
Read more
Report
Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?
Bellicum may disappoint investors yet again in 2018. Here's why.
Read more
Report
Show more news
Financials
Total raised
$35M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $35M | Details |